Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (March 2025)
20 slides from Preveceutical Medical's investor presentation, March 2025
Slide 1: Corporate Presentation: Sol-Gel Deliver Platform
CORPORATE PRESENTATION SOL-GEL DELIVER PLATFORM March 2025 CSE: PREV OTCQB: PRVCF FSE: 18H
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical® Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced
Slide 3: Corporate Overview
CORPORATE OVERVIEW Preventive health sciences company with corporate offices in Vancouver, Canada, and wholly owned subsidiary in Brisbane, Australia. Leveraging innovative science & technology to enhance natural products as novel targeted therapeutics in a diverse portfolio of R&D programs addressi
Slide 4: Sol-Gel Platform: Revolutionizing Drug Delivery to the Brain
SOL-GEL PLATFORM: REVOLUTIONIZING DRUG DELIVERY TO THE BRAIN The Sol-Gel platform is an adaptable water- based formulation that uses exclusively FDA- approved excipients. It allows for controlled and sustained drug delivery. This innovative system can deliver therapeutics directly to the brain by by
Slide 5: What Is the Sol-Gel?
WHAT IS THE SOL-GEL? A solution that is engineered to rapidly gel upon contact with mucosa Controlled and sustained release (nanomicellar formulation) to and through the mucosa Formulated to be compatible with APIs of various chemical nature (siRNA, mRNA, AB, FAB, small molecule, etc.) Room Temperat
Slide 6: Versatile Administration & Patented Technology
VERSATILE ADMINISTRATION & PATENTED TECHNOLOGY Multiple Routes Patented Amenable to nasal, buccal, Proprietary technology for throat, ear, topical, vaginal targeted drug delivery. and rectal administration. Sol-Gel offers sustained delivery - from hours to days
Slide 7: Sol-Gel Delivery: Why Nose-to-Brain?
SOL-GEL DELIVERY WHY NOSE-TO-BRAIN? 01 02 03 04 Direct Drug Delivery to Brain Challenges with Oral Route BBB Permeability Leverage Olfactory Pathway Patient outcomes of Rapid breakdown of Difficult to reach the brain Ideal pathway to deliver CNS(Central Nervous enzymes in gut; incidences with drugs
Slide 8: Sol-Gel Platform Technology & Device
SOL-GEL PLATFORM TECHNOLOGY & DEVICE Conventional nasal sprays deliver Olfactory mucosa targeting, rapid sol- formulation throughout the nasal cavity, to-gel transition, muco-retention and and are rapidly cleared… sustained delivery • Anterior & posterior leakage • Exclusive olfactory targeting • Ra
Slide 9: Key Applications & Therapeutic Targets
KEY APPLICATIONS & THERAPEUTIC TARGETS “Sol-gel technology has certainly shown significant CNS Disorders promise in laboratory testing at this point. Eventually, Targets the central nervous system for neurological and I would like to see this proprietary technology be psychiatric conditions. success
Slide 10: Functional Advantages
FUNCTIONAL ADVANTAGES ✓Innovative delivery system ✓Micro-dosing to potentially reduce existing side effects ✓Sustained release; potentially for bi-weekly dosing ✓precision delivery; higher bioavailability ✓Significant potential across CNS disorders ✓Amenable to nasal, buccal, throat, ear, topical, v
Slide 11: PreveCeutical Team
PREVECEUTICAL TEAM Stephen Van Deventer Mak Jawadekar PhD - Chairman and Chief Executive Officer – President, Chief Science Officer and Director Mr. Van Deventer is an experienced businessman and Dr. Jawadekar completed his Ph.D. in Pharmaceutics at the corporate director. Specializing in internatio
Slide 12: PreveCeutical Team
PREVECEUTICAL TEAM Linnéa Olofsson PhD Kathy Rokita CPA – Director – Director Dr. Olofsson is an accomplished biophysicist with 12 years of Ms. Rokita is a finance, operations, and strategey-focused laboratory research experience in academia, and 3 years executive having extensive experience with la
Slide 13: PreveCeutical Team
PREVECEUTICAL TEAM C. Evan Ballantyne Harry Parekh PhD, BSc Hons I – Director - Chief Research Officer Mr. Ballantyne has extensive executive leadership experience Based at the University of Queensland’s (UQ) Pharmacy and has spent the last 20 years as a public and private Australia Centre of Excell
Slide 14: PreveCeutical Team
PREVECEUTICAL TEAM Louis Lapointe Sydney Cole – Director of Business Development – Executive Assistant & Office Manager Mr. Lapointe is a business professional and investment banker Ms. Cole has held Administration Support and trainer roles within with twenty-five years of experience across a myriad
Slide 15: PreveCeutical Australia Team
PREVECEUTICAL AUSTRALIA TEAM PreveCeutical® has established a wholly- owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests. The Australian team, which will be led by Stephen Van Deventer, the Chief Executive Officer, will work closely with Dr. Harr
Slide 16: Research Collaborators
RESEARCH COLLABORATORS Dr. Rakesh Veedu is leading the Precision Nucleic Professor Grant Ramm is currently the head of the Acids Theranostics Group, as a McCusker Research Hepatic Fibrosis Laboratory and Coordinator of the Fellow with the Perron Institute for Neurological and Cell and Molecular Biol
Slide 17: Research Collaborators
RESEARCH COLLABORATORS Dr. Ajit Shetty Aditya Bahl Dr. Shetty has extensive pharmaceutical experience Mr. Bahl brings over 20 years of experience in leading commercial and supply chain operations pharmaceutical marketing and clinical as well as significant educational background development and is k
Slide 18: Research Collaborators
RESEARCH COLLABORATORS Dr. Bryan Jones Dr. Jones has more than 30 years of experience with biotech and specialty pharmaceutical companies with roles in product and business development. Currently, he is the COO of Aardvark Therapeutics. Previously, he served as COO and Co-Founder of Sollis Therapeut
Slide 19: Partners
PARTNERS LN 0! THE UNIVERSITY vw DUMOULIN Ny} OF QUEENSLAND MURDOCH [B) BLACK AUSTRALIA UNIVERSITY PERTH, WESTERN AUSTRALIA RUA ae IP Amplified RAS ] QIMR Berghofer grjffit i” Medical Research Institute ( PREVECEBTICAL
Slide 20: Please Contact
Stephen Van Deventer info@preveceutical.com PLEASE Investor Relations CONTACT ir@preveceutical.com 1 (604) 416-7777
PreveCeutical Medical — Investor Presentation (March 2025) on 6ix